A federal judge said Amgen must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders ...

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Family Heart Foundation unveiled the Cholesterol Connect program for LDL-C Awareness Day, aiming to make it easier for people ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

Founded by renowned and experienced African biostatisticians, Optima Clinical aims to revolutionize data management and ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

Biosimilar medications are garnering attention as a promising alternative to traditional and very expensive biologic drugs.

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

A Missouri mother and her lawyers this week will aim to convince a jury that Abbott , Reckitt's Mead Johnson and St. Louis Children's Hospital are responsible for a severe intestinal illness that she ...

Shane Lowry has had a solid if unspectacular run since returning to the DP World Tour, but he enjoyed a memorable Spanish ...